Peripheral arterial disease (PAD) affects a considerable percentage of the population. The manifestations of this disease are not always clinically overt. As a result, PAD remains underdiagnosed and undertreated. PAD is not just a disease of the peripheral arteries, but also an indication of generalized vascular atherosclerosis. PAD patients also have a high prevalence of other arterial diseases, such as coronary/carotid artery disease and abdominal aortic aneurysms. PAD is also a predictor of increased risk of lung and other cancers. The most often used examination for the establishment of the diagnosis of PAD, the ankle-brachial pressure index (ABPI), is also a predictor of generalized atherosclerosis, future cardiovascular events and cardiovascular mortality. Several markers that have been linked with PAD (e.g. C-reactive protein, serum bilirubin levels) may also have predictive value for other conditions besides PAD (e.g. kidney dysfunction). The management of PAD should therefore not be restricted to the peripheral circulation but should include measurements to manage and decrease the systemic atherosclerotic burden of the patient.
RookeTWHirschATMisraS. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Interventional Radiology; Society for Vascular Medicine; Society for Vascular Surgery. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine; Society for Vascular Surgery. J Vasc Surg. 2011;54(5):e32–e58.
3.
HiattWRGoldstoneJSmithSCJr; American Heart Association Writing Group 1. Atherosclerotic Peripheral Vascular Disease Symposium II: nomenclature for vascular diseases. Circulation. 2008;118(25):2826–2829.
4.
StansbyGMisterRFowkesG. Prospective Registry and Evaluation of Peripheral Arterial Risks, Events and Distribution Investigators. High risk of peripheral arterial disease in the United Kingdom: 2-year results of a prospective registry. Angiology. 2011;62(2):111–118.
5.
MukherjeeDLingamPChetcutiS. Missed opportunities to treat atherosclerosis in patients undergoing peripheral vascular interventions: insights from the University of Michigan Peripheral Vascular Disease Quality Improvement Initiative (PVD-QI2). Circulation. 2002;106(15):1909–1912.
6.
ShahAMBanerjeeTMukherjeeD. Coronary, peripheral and cerebrovascular disease: a complex relationship. J Indian Med Assoc. 2010;108(5):292–294.
7.
MukherjeeDChoL. Peripheral arterial disease: considerations in risks, diagnosis, and treatment. J Natl Med Assoc. 2009;101(10):999–1008.
8.
TakigawaMYoshimutaTAkutsuKTakeshitaSYokoyamaN. Prevalence and predictors of coexistent silent atherosclerotic cardiovascular disease in patients with abdominal aortic aneurysm without previous symptomatic cardiovascular diseases. Angiology. 2012;63(5):380–385.
9.
ParaskevasKIMikhailidisDPLiapisCD. Internal carotid artery occlusion: association with atherosclerotic disease in other arterial beds and vascular risk factors. Angiology. 2007;58(3):329–335.
10.
BadhekaAORathodADBharadwajAS. Outcomes and risk prediction model for peripheral arterial disease in patients with stable coronary artery disease. Angiology. 2011;62(6):473–479.
11.
WilsonWRFitridgeRAWeekesAJMorganCTavellaRBeltrameJF. Quality of life in patients with peripheral arterial disease and chronic stable angina. Angiology. 2012;63(3):223–228.
12.
DhaliwalDMukherjeeD.Peripheral arterial disease: Epidemiology, natural history, diagnosis and treatment. Int Angiol. 2007;16(2):36–44.
13.
ParaskevasKIKotsikorisIKoupidisSAGiannoukasADMikhailidisDP. Ankle-brachial index: a marker of both peripheral arterial disease and systemic atherosclerosis as well as a predictor of vascular events. Angiology. 2010;61(6):521–523.
14.
RabkinSWChanSHSweeneyC. Ankle-brachial index as an indicator of arterial stiffness in patients without peripheral arterial artery disease. Angiology. 2012;63(2):150–154.
15.
KolliasAStergiouGSDolanEO’BrienE.Ambulatory arterial stiffness index: A systematic review and meta-analysis. Atherosclerosis. 2012;224(2):291–301.
16.
LaurentSAlivonMBeaussierHBoutouyrieP. Aortic stiffness as a tissue biomarker for predicting future cardiovascular events in asymptomatic hypertensive subjects. Ann Med. 2012;44(suppl 1):S93–S97.
17.
SukhijaRAronowWSYalamanchiliKPetersonSJFrishmanWHBabuS. Association of ankle-brachial index with severity of angiographic coronary artery disease in patients with peripheral arterial disease and coronary artery disease. Cardiology. 2005;103(3):158–160.
18.
WangHYHanPZhangWH. Serum bilirubin level is negatively correlated with disease progression of peripheral arterial disease: an observational cohort study. Angiology. 2012;63(4):248–253.
19.
FanJJouniHKhaleghiMBaileyKRKulloIJ. Serum N-terminal pro-B-type natriuretic peptide levels are associated with functional capacity in patients with peripheral arterial disease. Angiology. 2012;63(6):435–442.
20.
KhandanpourNJenningsBArmonMP. Do novel risk biomarkers reflect the severity of peripheral arterial disease?Angiology. 2011;62(2):126–133.
21.
StenvinkelPLindholmB. C-reactive protein in end-stage renal disease: are there reasons to measure it?Blood Purif. 2005;23(1):72–78.
22.
StenvinkelP. Inflammation in end-stage renal disease: the hidden enemy. Nephrology (Carlton). 2006;11(1):36–41.
23.
DeetmanPEZelleDMHoman van der HeideJJNavisGJGansROBakkerSJ.Plasma bilirubin and late graft failure in renal transplant recipients. Transpl Int. 2012;25(8):876–881.
24.
ChenYHHungSCTarngDC. Serum bilirubin links UGT1A1*28 polymorphism and predicts long–term cardiovascular events and mortality in chronic hemodialysis patients. Clin J Am Soc Nephrol. 2011;6(3):567–574.
25.
ParaskevasKIGiannoukasADMikhailidisDP. Renal function impairment in peripheral arterial disease: an important parameter that should not be neglected. Ann Vasc Surg. 2009;23(5):690–699.
26.
YoussefFGuptaPSeifalianAMMyintFMikhailidisDPHamiltonG. The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology. 2004;55(1):53–62.
27.
AlnaebMEAlobaidNSeifalianAMMikhailidisDPHamiltonG. Statins and peripheral arterial disease: potential mechanisms and clinical benefits. Ann Vasc Surg. 2006;20(5):696–705.
28.
TsiaraSElisafMMikhailidisDP. Early vascular benefits of statin therapy. Curr Med Res Opin. 2003;19(6):540–556.
29.
TsouliSGLiberopoulosENKiortsisDNMikhailidisDPElisafMS. Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence. J Cardiovasc Pharmacol Ther. 2006;11(1):1–15.
30.
FallujiNMukherjeeD. Contemporary management of infrapopliteal peripheral arterial disease. Angiology. 2011;62(6):490–499.
31.
ParaskevasKIGiannoukasADMikhailidisDP.Statins and infrainguinal vascular bypass procedures. Curr Vasc Pharmacol. 2013;11(1):51–57.
32.
LohSAHowellBSRockmanCB. Mid- and long-term results of the treatment of infrainguinal arterial occlusive disease with precuffed expanded polytetrafluoroethylene grafts compared with vein grafts. Ann Vasc Surg. [published online September 18, 2012]
33.
MendizOAFavaCMValdiviesoLRLevGAVillagraLG. Angioplasty for treatment of isolated below-the-knee arterial stenosis in patients with critical limb ischemia. Angiology. 2011;62(5):359–364.
34.
StansbyGWilliamsR. Angioplasty for treatment of isolated below-the-knee arterial stenosis in patients with critical limb ischemia. Angiology. 2011;62(5):357–358.
35.
TauteBMThommesSTauteRPodhaiskyH. The possible risk of cancer in claudicants. Angiology. 2011;62(7):579–584.
36.
ParaskevasKIMikhailidisDPVeithFJ. Patients with peripheral arterial disease, abdominal aortic aneurysms and carotid artery stenosis are at increased risk for developing lung and other cancers. Int Angiol. 2012;31(4):404–405.
37.
HullMKantP. Atherosclerosis and colorectal carcinogenesis: shared risk factors or common pathogenesis?Digestion. 2010;81(1):16–17.
38.
CatalanoCNapoliANardisPGFraioliFPassarielloR. Incidental finding of lung cancer in patients studied by MDCT for atherosclerotic disease. Eur Radiol. 2005;15(9):2031–2033.
